Targeting tumour necrosis factor-α in corticosteroid-dependent asthma

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 3, 2006, Pages 471-473

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Asthma; Etanercept; TNF

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; EOSINOPHIL; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LUNG LAVAGE; MAINTENANCE THERAPY; NEUTROPHIL; PATHOPHYSIOLOGY; PATIENT MONITORING; QUESTIONNAIRE; SEVERE PERSISTENT ASTHMA; STIMULUS RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745447239     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.3.471     Document Type: Article

References (9)

1. WENZEL SE, SZEFLER SJ, LEUNG DY et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care. Med. (1997) 156(3 Pt 1):737-743.
2. RUSSO C, POLOSA R: TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin. Sci. (Lond) (2005) 109(2):135-142.
3. AMRANI Y, CHEN H, PANETTIERI RA, Jr.: Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir. Res. (2000) 1(1):49-53.
4. GOSSET P, TSICOPOULOS A, WALLAERT B et al.: Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J. Allergy Clin. Immunol. (1991) 88(4):561-571.
5. OHKAWARA Y, LEI XF, STAMPFLI MR et al.: Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am. J. Respir. Cell Mol. Biol. (1997) 16(5):510-520.
6. THOMAS PS, HEYWOOD G: Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax (2002) 57(9):774-778.
7. HOWARTH PH, BABU KS, ARSHAD HS et al.: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax (2005) 60(12):1012-1018.
8. BODEY KJ, SEMPER AE, REDINGTON AE et al.: Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy (1999) 54(10):1083-1093.
9. WILSON SJ, WALLIN A, DELLA-CIOPPA G, SANDSTROM T, HOLGATE ST: Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am. J. Respir. Crit. Care Med. (2001) 164(6):1047-1052.